Navigation Links
Pivotal Data on Bronchial Thermoplasty from the Asthma Intervention Research 2 (AIR2) Trial to be Presented at ATS 2009
Date:5/6/2009

New non-drug procedure for severe asthma featured in eight presentations at annual conference in San Diego

SUNNYVALE, Calif., May 6 /PRNewswire/ -- Asthmatx released today the schedule of presentations featuring its novel Alair(R) Bronchial Thermoplasty System at ATS 2009, the International Conference of the American Thoracic Society (ATS), which will take place in San Diego, Calif., May 15-20. The schedule includes the one year results from the pivotal AIR2 Trial, which was designed to evaluate the safety and effectiveness of bronchial thermoplasty delivered by the Alair System, which is an investigational procedure that may change the standard of care for millions of patients suffering from asthma.

"We're looking forward to an exciting ATS meeting with numerous scientific presentations focusing on bronchial thermoplasty and its potential to elevate the standard of care for patients suffering from severe asthma," said Glen French, CEO of Asthmatx. "The selection by the ATS Program Committee of the AIR2 data for inclusion in the late breaking clinical trials session further reflects the importance of these data to the asthma community."

The full schedule of oral and poster presentations surrounding bronchial thermoplasty at ATS 2009 include:

    Monday, May 18, 2009

    ORAL PRESENTATIONS: 1:30 - 4:00 PM

    Session B92 Mini-Symposium: New treatment approaches for asthma and
     allergy

    3:20-3:35 PM      Efficacy of Bronchial Thermoplasty (BT) in Patients with
                      Severe Asthma: The AIR2 Trial, Mario Castro, MD, St.
                      Louis, MO

    3:35-3:55 PM      "Bronchial Thermoplasty," Invited Featured Speaker:
                      Gerard Cox, MB, Hamilton, ON, Canada

    POSTER PRESENTATIONS: 8:15 AM - 4:00 PM (Authors will be at their
     respective posters from 10:45 AM -12:30 PM)

    Session B31: Asthma Therapeutics -- Studies in Humans

        -- Bronchial Thermoplasty, a Novel Therapeutic Procedure for Severe
           Asthma; A Detailed Procedure and Technique Discussion, Martin
           Mayse, MD, St. Louis, MO
        -- AIR2 Trial: Execution of a Sham-Controlled Double-Blind Study of a
           Novel Device for the Treatment of Severe Asthma, Gerard Cox, MB,
           Hamilton, ON, Canada
        -- Asthma-Related ER Visits and Hospitalizations Following Bronchial
           Thermoplasty (BT) in Patients with Severe, Symptomatic Asthma,
           Michael Wechsler, MD, Boston, MA
        -- Safety of Bronchial Thermoplasty (BT) in Patients with Severe,
           Symptomatic Asthma: Positive Safety Profile in the AIR2 Trial,
           Pallav Shah, MD, London, UK
        -- Long Term Safety of Bronchial Thermoplasty (BT): 3 year Data from
           Multiple Studies, Gerard Cox, MB, Hamilton, ON, Canada


    Tuesday, May 19, 2009

    LATE BREAKING CLINICAL TRIALS SESSSION: 1:30 - 4:00 PM

    ORAL PRESENTATION:

    2:45 - 3:10 PM    Bronchial Thermoplasty as Treatment for Severe Asthma:
                      Results of a Multicenter, Randomized, Sham-Controlled
                      Clinical Trial, Mario Castro, MD, St. Louis, MO

About Bronchial Thermoplasty Delivered by the Alair System

Bronchial thermoplasty is a novel non-drug treatment for asthma. The treatment is performed through the working channel of a standard flexible bronchoscope that is introduced through a patient's nose or mouth, and into their lungs. The tip of the small diameter Alair Catheter is expanded to contact the walls of targeted airways. Controlled thermal energy is then delivered to the airway walls to reduce the amount of airway smooth muscle that narrows the airways in patients with asthma during an asthma attack. The minimally invasive procedure, like many other flexible endoscopy procedures, is done under light anesthesia and the patient returns home the same day. In the period immediately following bronchial thermoplasty, there is an expected increase and worsening of respiratory-related symptoms, which are of the type expected following bronchoscopy in patients with asthma. These typically occur within a day of the procedure and resolve on average within 7 days with standard care.

CAUTION: Alair System is an Investigational Device. It is limited by United States law to investigational use. To be used by Qualified Investigators only.

Alair is a registered trademark of Asthmatx, Inc.

About Asthmatx

Asthmatx is developing catheter-based medical devices for the treatment of asthma. Asthmatx has developed the Alair System to perform an investigational outpatient procedure called bronchial thermoplasty. The Alair System from Asthmatx was awarded "Best of 2006" by Popular Science Magazine and bronchial thermoplasty was named one of the "Top Ten Medical Innovations for 2007" by the prestigious Cleveland Clinic Foundation. The Alair System has received a CE Mark for use in the European Union. For more information on Asthmatx visit www.asthmatx.com.


'/>"/>
SOURCE Asthmatx
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
2. Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial
3. WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD
4. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
5. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
6. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
7. Pivotal Emory study focuses on teens at risk for psychosis
8. Intellect Neurosciences, Inc. Validates Pivotal European Patent for Alzheimers Monoclonal Antibody Platform
9. SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
10. Pioneer(R) Surgical Technologys NuBac(R) Nucleus Replacement Device Wins FDA Approval for IDE Pivotal Study
11. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: